Voice Rest and Injection Laryngoplasty
Voice Rest and Injection Laryngoplasty: A Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: James J Daniero, MD
- Phone Number: 4349242040
- Email: jjd5h@uvahealth.org
Study Locations
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- Recruiting
- University of Virginia
-
Contact:
- James J Daniero, MD
- Phone Number: 434-924-2040
- Email: jjd5h@uvahealth.org
-
Contact:
- Elena Miller
- Phone Number: 4342433607
- Email: em8zk@uvahealth.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >18 years old
Undergoing injection augmentation by Dr. McGarey, Dr. Torrecillas, or Dr. Daniero for the following conditions:
- Glottic insufficiency from atrophy, scar, or presbylarynx
- Unilateral or bilateral vocal fold immobility
- Unilateral or bilateral vocal fold hypomobility
Exclusion Criteria:
- Prior history of head and neck radiation.
- Active or recent (within 3 months) chemotherapy.
- Age <18 years old
- Incarcerated individuals will be excluded due to inability to enroll in post-intervention clinic visit
- Presence of posterior glottic stenosis
- Presence of acute laryngeal injury
- Bedside inpatient injection augmentation
- Vocal fold Injection with steroids or cidofovir
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Voice Rest
48 hours of voice rest prescribed following injection
|
Voice rest restricting patient phonation
|
|
Experimental: No voice rest
No voice rest required following injection
|
No Voice rest
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient-perceived voice improvement
Time Frame: 2 weeks
|
Voice Handicap Index - 10. Scale range 0-40.
Lower score designates lower voice impairment
|
2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
GRBAS- Grade, Roughness, Breathiness, Asthenia, Strain
Time Frame: 2 weeks
|
Clinician-perceived improvement in voice.
Range is 0-15.
Lower score indicates lower perceived vocal impairment
|
2 weeks
|
|
Phonation threshold pressure
Time Frame: 2 weeks
|
Objective aerodynamic measure
|
2 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: James J Daniero, MD, University of Virginia
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HSR220245
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.